Volume 8, Issue 4 (11-2023)
J Res Dent Maxillofac Sci 2023, 8(4): 286-290 |
Back to browse issues page
Ethics code: Not Applicable
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shirani A M, Khosravi M, Ardestani M, Ashtari F. Pemphigus Vulgaris in a Patient with Multiple
Sclerosis: A Case Report with 7 Years of Follow Up. J Res Dent Maxillofac Sci 2023; 8 (4) :286-290
URL: http://jrdms.dentaliau.ac.ir/article-1-477-en.html
URL: http://jrdms.dentaliau.ac.ir/article-1-477-en.html
1- Department of Oral Medicine, School of Dentistry, Isfahan Branch, Islamic Azad University, Isfahan, Iran
2- Faculty of Dentistry, Isfahan Branch, Islamic Azad University, Isfahan, Iran ,khosravi.mari@yahoo.com
3- Faculty of Dentistry, Isfahan Branch, Islamic Azad University, Isfahan, Iran
4- Neurosurgery Department, Medical Faculty, Isfahan University of Medical Sciences, Isfahan, Iran
2- Faculty of Dentistry, Isfahan Branch, Islamic Azad University, Isfahan, Iran ,
3- Faculty of Dentistry, Isfahan Branch, Islamic Azad University, Isfahan, Iran
4- Neurosurgery Department, Medical Faculty, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract: (961 Views)
| Background and Aim: Pemphigus vulgaris (PV) is a severe life-threatening autoimmune disease that causes intraepithelial blisters. PV has been reported in association with some autoimmune diseases. But only few cases (fewer than 10 reports according to literature search) have been reported regarding the association of PV with multiple sclerosis (MS). MS is a life-threatening, inflammatory demyelinating disease, causing severe disability. Case Presentation: Our patient was a 40-year-old female complaining of gingival ulcers. She had MS for the past 10 years. Biopsy and immunoassay were done and PV was confirmed. The patient has been followed up for 7 years so far. Conclusion: It is necessary to pay attention to mild oral ulcers in MS patients because they may be related to severe blistering diseases like PV. |
Type of Study: Case report |
Subject:
Oral medicine
References
1. Chesworth BM, Hamilton CB, Walton DM, Benoit M, Blake TA, Bredy H, et al. Reliability and validity of two versions of the upper extremity functional index. Physiother Can. 2014 Sum-mer;66(3):243-53. [DOI:10.3138/ptc.2013-45] [PMID] []
2. Zawar V, Pawar M, Kumavat S. Recurrent Paronychia as a Presenting Manifestation of Pemphigus Vulgaris: A Case Report. Skin Appendage Disord. 2017 Mar;3(1):28-31. [DOI:10.1159/000455881] [PMID] []
3. Ruocco V, Ruocco E, Lo Schiavo A, Brunetti G, Guerrera LP, Wolf R. Pemphigus: etiology, pathogenesis, and inducing or trig-gering factors: facts and controversies. Clin Dermatol. 2013 Jul-Aug;31(4):374-81. [DOI:10.1016/j.clindermatol.2013.01.004] [PMID]
4. Kavala M, Kural E, Kocaturk E, Zindanci I, Turkoglu Z, Can B. The evaluation of thyroid diseases in patients with pemphigus vulgaris. ScientificWorldJournal. 2012;2012: 146897. [DOI:10.1100/2012/146897] [PMID] []
5. Cruickshank TM, Reyes AR, Ziman MR. A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease. Medicine (Baltimore). 2015 Jan;94(4):e411. [DOI:10.1097/MD.0000000000000411] [PMID] []
6. Dutta R, Trapp BD. Relapsing and progressive forms of multi-ple sclerosis: insights from pathology. Curr Opin Neurol. 2014 Jun;27(3):271-8. [DOI:10.1097/WCO.0000000000000094] [PMID] []
7. Zhang GQ, Meng Y. Oral and craniofacial manifestations of multiple sclerosis: implications for the oral health care provider. Eur Rev Med Pharmacol Sci. 2015 Dec;19(23): 4610-20.
8. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics. 2013 Jan;10(1):2-18. [DOI:10.1007/s13311-012-0163-4] [PMID] []
9. Meiner Z, Zlotogorski A, Brautbar C. Pemphigus associated with multiple sclerosis. Clin Exp Dermatol. 1992 May; 17(3): 217. [DOI:10.1111/j.1365-2230.1992.tb00213.x] [PMID]
10. Friedel J, Jeandel C, Abensour M, Heid E. Multiple sclerosis and autoimmune skin bullae: a case of pemphigus vul-garis. Dermatologica. 1987;175(3):159-60. [DOI:10.1159/000248818] [PMID]
11. Burket's oral medicine.Glick M,Greenberg M,Lockhart PB,ChallacombehSJ.Wiley Blackwell.13th edition,2021,61.
12. El-Darouti MA, Hegazy RA, Abdel Hay RM, El Hawary MS, Tawdy AM, Fawzy MM, et al. Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial. Arch Dermatol Res. 2015 May;307(4):299-307. [DOI:10.1007/s00403-014-1522-2] [PMID]
13. Lee SH, Hong WJ, Kim SC. Analysis of Serum Cytokine Profile in Pemphigus. Ann Dermatol. 2017 Aug;29(4):438-45. [DOI:10.5021/ad.2017.29.4.438] [PMID] []
14. Kridin K. Pemphigus group: overview, epidemiology, mortal-ity, and comorbidities. Immunol Res. 2018 Apr;66(2): 255-70. [DOI:10.1007/s12026-018-8986-7] [PMID]
15. Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol. 2018 Feb;54(1):1-25. [DOI:10.1007/s12016-017-8662-z] [PMID]
16. Yoshimura K, Ishii N, Hamada T, Abe T, Ono F, Hashikawa K, et al. Clinical and immunological profiles in 17 Japanese patients with drug-induced pemphigus studied at Kurume University. Br J Dermatol. 2014 Sep;171(3):544-53. [DOI:10.1111/bjd.12925] [PMID]
17. Ramseur WL, Richards F, 2nd, Duggan DB. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy. Cancer. 1989 May 15;63(10):2005-7.
https://doi.org/10.1002/1097-0142(19890515)63:10<2005::AID-CNCR2820631023>3.0.CO;2-P [DOI:10.1002/1097-0142(19890515)63:103.0.CO;2-P] [PMID]
18. Feliciani C, Cozzani E, Marzano AV, Caproni M, Di Zenzo G, Calzavara-Pinton P; "Cutaneous Immunology" group of SIDe-MaST. Italian Guidelines in Pemphigus - adapted from the Euro-pean Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV). G Ital Dermatol Venereol. 2018 Oct;153(5):599-608. [DOI:10.23736/S0392-0488.18.06073-X]
19. Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, Kowalewski C, Jedlickova H, Kárpáti S, Marinovic B, Mimouni D, Uzun S, Yayli S, Hertl M, Borradori L. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the Euro-pean Academy of Dermatology and Venereology. Br J Dermatol. 2015 Apr;172(4):867-77. [DOI:10.1111/bjd.13717] [PMID]
20. Arpita R, Monica A, Venkatesh N, Atul S, Varun M. Oral Pem-phigus Vulgaris: Case Report. Ethiop J Health Sci. 2015 Oct;25(4):367-72. [DOI:10.4314/ejhs.v25i4.11]
21. Das D, Anand V, Khandpur S, Sharma VK, Sharma A. T helper type 1 polarizing gammadelta T cells and Scavenger receptors contribute to the pathogenesis of Pemphigus vulgaris. Immunology. 2018 Jan;153(1):97-104. [DOI:10.1111/imm.12814] [PMID] []
22. Narla S, Silverberg JI. Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. J Am Acad Dermatol. 2020 Mar;82(3):586-95. [DOI:10.1016/j.jaad.2019.07.029] [PMID]
23. Ljubojević S, Lipozencić J, Brenner S, Budimcić D. Pemphigus vulgaris: a review of treatment over a 19-year peri-od. J Eur Acad Dermatol Venereol. 2002 Nov;16(6):599-603. [DOI:10.1046/j.1468-3083.2002.00504.x] [PMID]
24. Shabbir SG, Hassan M, Kazmi SA, Suhail S. Myasthenia gravis and pemphigus vulgaris. J Pak Med Assoc. 1984 Nov; 34(11):349-51.
25. Leshem YA, Katzenelson V, Yosipovitch G, David M, Mimouni D. Autoimmune diseases in patients with pemphigus and their first-degree relatives. Int J Dermatol. 2011 Jul;50(7):827-31. [DOI:10.1111/j.1365-4632.2010.04818.x] [PMID]
26. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011 Mar;131(3):631-6. [DOI:10.1038/jid.2010.357] [PMID]
27. Amber KT, Zikry J, Hertl M. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? HLA. 2017 Mar;89(3):127-34. [DOI:10.1111/tan.12960] [PMID]
28. Daneshpazhooh M, Behjati J, Hashemi P, Shamohammadi S, Mortazavi H, Nazemi MJ, et al. Thyroid autoimmunity and pem-phigus vulgaris: is there a significant association? J Am Acad Dermatol. 2010 Feb;62(2):349-51. [DOI:10.1016/j.jaad.2009.05.024] [PMID]
29. Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, et al. A systematic review of the incidence and preva-lence of autoimmune disease in multiple sclerosis. Mult Scler. 2015 Mar;21(3):282-93. [DOI:10.1177/1352458514564490] [PMID] []
30. Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD.Association Between Pemphigus and Neurologic Diseases. JAMA Dermatol. 2018 Mar 1;154(3):281-5. [DOI:10.1001/jamadermatol.2017.5799] [PMID] []
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
